Get notified when NUS files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Standing Risk Factors

  • Goodwill Impairment (unchanged) — Manufacturing reporting unit recorded $78.9M goodwill impairment in Q2 2026 due to stock-price decline and forecast deterioration.
NYSE: NUS NU SKIN ENTERPRISES, INC. 10-Q

Revenue fell 17.1% to $320.1M; goodwill impairment and tax allowance drove Q2 EPS to $(5.14)

Filed August 10, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 8, 2025 · ~2 min read

Key Changes

  • high

    Q2 2026 revenue fell 17.1% YoY to $320.1M (vs 12% decline in Q2 2025), driven by macroeconomic challenges, Prysm iO product-transition friction, and sales-compensation-plan changes.

    MD&A: Revenue verify on EDGAR →
  • high

    Q2 2026 EPS swung to $(5.14) from $0.43 in Q2 2025, driven by a $78.9M goodwill impairment on the manufacturing segment, a $167.5M U.S. deferred-tax valuation allowance, and operating loss of $59.3M.

    MD&A: Earnings per Share verify on EDGAR →
  • high

    Company established $167.5M valuation allowance against U.S. deferred tax assets in Q2 2026, citing three-year cumulative U.S. losses from goodwill and intangible impairments; effective tax rate was (295.4)%.

    Notes: Income Taxes verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (CRWD 10-Q) is open in full — no account needed.

Partner

Trade NUS commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Aug 11, 2026 · How we verify